IFNB1 and myeloid sarcoma: Several disease-modifying therapies (DMT), including IFNβ [109] natalizumab [74,76,98,109,111], mitoxantrone [76], daclizumab [106], and fingolimod [75], have been shown to significantly reduce CSF CHI3L1 levels compared to untreated patients across all MS clinical types (Table 1).